Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
19
KMTS Quote, Financials, Valuation and Earnings
Last price:
$22.42
Seasonality move
:
--
Day range:
$22.17 - $23.36
52-week range:
$13.25 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.85x
P/B ratio:
6.66x
Volume:
493.7K
Avg. volume:
244.7K
1-year change:
--
Market cap:
$1.1B
Revenue:
$59.8M
EPS (TTM):
-$2.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$22.9M | -$0.60 | 51.57% | -24.07% | $29.00 |
|
AZTA
Azenta, Inc.
|
$147.1M | $0.13 | 3.4% | 86.12% | $38.67 |
|
BIO
Bio-Rad Laboratories, Inc.
|
$687.7M | $2.70 | 0.05% | -13.46% | $324.00 |
|
BNGO
Bionano Genomics, Inc.
|
$7.9M | -$1.90 | 29.66% | -82.39% | $7.50 |
|
BRKR
Bruker Corp.
|
$963.8M | $0.65 | -1.03% | 101.14% | $48.43 |
|
HBIO
Harvard Bioscience, Inc.
|
$23.1M | $0.04 | -2.41% | -99.56% | $2.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$22.92 | $29.00 | $1.1B | -- | $0.00 | 0% | 15.85x |
|
AZTA
Azenta, Inc.
|
$24.54 | $38.67 | $1.1B | -- | $0.00 | 0% | 1.89x |
|
BIO
Bio-Rad Laboratories, Inc.
|
$280.19 | $324.00 | $7.6B | 10.04x | $0.00 | 0% | 2.96x |
|
BNGO
Bionano Genomics, Inc.
|
$1.12 | $7.50 | $11.4M | -- | $0.00 | 0% | 0.13x |
|
BRKR
Bruker Corp.
|
$39.27 | $48.43 | $6B | 77.08x | $0.05 | 0.51% | 1.74x |
|
HBIO
Harvard Bioscience, Inc.
|
$0.57 | $2.00 | $25.3M | -- | $0.00 | 0% | 0.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
21.45% | 0.000 | 3.43% | 5.32x |
|
AZTA
Azenta, Inc.
|
3.08% | 2.864 | 3.56% | 2.22x |
|
BIO
Bio-Rad Laboratories, Inc.
|
15.67% | 0.744 | 16.94% | 3.89x |
|
BNGO
Bionano Genomics, Inc.
|
25.67% | -0.041 | 103.34% | 1.58x |
|
BRKR
Bruker Corp.
|
45.4% | 0.803 | 28.49% | 0.75x |
|
HBIO
Harvard Bioscience, Inc.
|
75.26% | 3.328 | 218.87% | 0.35x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$11.4M | -$31.8M | -77.65% | -105.99% | -140.73% | -$25.8M |
|
AZTA
Azenta, Inc.
|
$63.7M | -$4.9M | 1.64% | 1.7% | -3.28% | $14.7M |
|
BIO
Bio-Rad Laboratories, Inc.
|
$344.8M | $61.9M | 9.16% | 10.99% | 8.93% | $119.1M |
|
BNGO
Bionano Genomics, Inc.
|
$3.4M | -$8.5M | -58.02% | -84.77% | -115.9% | -$5.9M |
|
BRKR
Bruker Corp.
|
$449.6M | $116.8M | -0.19% | -0.39% | 11.95% | $207.2M |
|
HBIO
Harvard Bioscience, Inc.
|
$11.2M | $245K | -68.29% | -155.33% | 1.19% | $482K |
Kestra Medical Technologies Ltd. vs. Competitors
-
Which has Higher Returns KMTS or AZTA?
Azenta, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -3.49%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Azenta, Inc.'s return on equity of 1.7%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M AZTAAzenta, Inc.42.86% -$0.34 $1.8B -
What do Analysts Say About KMTS or AZTA?
Kestra Medical Technologies Ltd. has a consensus price target of $29.00, signalling upside risk potential of 26.53%. On the other hand Azenta, Inc. has an analysts' consensus of $38.67 which suggests that it could grow by 57.57%. Given that Azenta, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Azenta, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 AZTAAzenta, Inc.2 3 0 -
Is KMTS or AZTA More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.387, suggesting its more volatile than the S&P 500 by 38.666%.
-
Which is a Better Dividend Stock KMTS or AZTA?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or AZTA?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are smaller than Azenta, Inc. quarterly revenues of $148.6M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Azenta, Inc.'s net income of -$5.2M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 15.85x versus 1.89x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.15.85x -- $22.6M -$32.8M AZTAAzenta, Inc.1.89x -- $148.6M -$5.2M
-
Which has Higher Returns KMTS or BIO?
Bio-Rad Laboratories, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -52.36%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Bio-Rad Laboratories, Inc.'s return on equity of 10.99%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M BIOBio-Rad Laboratories, Inc.49.74% $26.65 $8.8B -
What do Analysts Say About KMTS or BIO?
Kestra Medical Technologies Ltd. has a consensus price target of $29.00, signalling upside risk potential of 26.53%. On the other hand Bio-Rad Laboratories, Inc. has an analysts' consensus of $324.00 which suggests that it could grow by 15.64%. Given that Kestra Medical Technologies Ltd. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Kestra Medical Technologies Ltd. is more attractive than Bio-Rad Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 BIOBio-Rad Laboratories, Inc.2 3 0 -
Is KMTS or BIO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bio-Rad Laboratories, Inc. has a beta of 1.183, suggesting its more volatile than the S&P 500 by 18.331%.
-
Which is a Better Dividend Stock KMTS or BIO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Rad Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Bio-Rad Laboratories, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or BIO?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are smaller than Bio-Rad Laboratories, Inc. quarterly revenues of $693.2M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Bio-Rad Laboratories, Inc.'s net income of $720M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Bio-Rad Laboratories, Inc.'s PE ratio is 10.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 15.85x versus 2.96x for Bio-Rad Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.15.85x -- $22.6M -$32.8M BIOBio-Rad Laboratories, Inc.2.96x 10.04x $693.2M $720M
-
Which has Higher Returns KMTS or BNGO?
Bionano Genomics, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -115.42%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Bionano Genomics, Inc.'s return on equity of -84.77%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M BNGOBionano Genomics, Inc.45.75% -$1.59 $67M -
What do Analysts Say About KMTS or BNGO?
Kestra Medical Technologies Ltd. has a consensus price target of $29.00, signalling upside risk potential of 26.53%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 569.64%. Given that Bionano Genomics, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Bionano Genomics, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 BNGOBionano Genomics, Inc.1 0 0 -
Is KMTS or BNGO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.686, suggesting its more volatile than the S&P 500 by 68.556%.
-
Which is a Better Dividend Stock KMTS or BNGO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or BNGO?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 15.85x versus 0.13x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.15.85x -- $22.6M -$32.8M BNGOBionano Genomics, Inc.0.13x -- $7.4M -$8.5M
-
Which has Higher Returns KMTS or BRKR?
Bruker Corp. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of 2.99%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Bruker Corp.'s return on equity of -0.39%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M BRKRBruker Corp.46.01% $0.10 $4.6B -
What do Analysts Say About KMTS or BRKR?
Kestra Medical Technologies Ltd. has a consensus price target of $29.00, signalling upside risk potential of 26.53%. On the other hand Bruker Corp. has an analysts' consensus of $48.43 which suggests that it could grow by 23.32%. Given that Kestra Medical Technologies Ltd. has higher upside potential than Bruker Corp., analysts believe Kestra Medical Technologies Ltd. is more attractive than Bruker Corp..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 BRKRBruker Corp.7 5 1 -
Is KMTS or BRKR More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.194, suggesting its more volatile than the S&P 500 by 19.4%.
-
Which is a Better Dividend Stock KMTS or BRKR?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.51% to investors and pays a quarterly dividend of $0.05 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or BRKR?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are smaller than Bruker Corp. quarterly revenues of $977.2M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Bruker Corp.'s net income of $29.2M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 15.85x versus 1.74x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.15.85x -- $22.6M -$32.8M BRKRBruker Corp.1.74x 77.08x $977.2M $29.2M
-
Which has Higher Returns KMTS or HBIO?
Harvard Bioscience, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -5.98%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M HBIOHarvard Bioscience, Inc.54.23% -$0.03 $56.9M -
What do Analysts Say About KMTS or HBIO?
Kestra Medical Technologies Ltd. has a consensus price target of $29.00, signalling upside risk potential of 26.53%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 253.67%. Given that Harvard Bioscience, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Harvard Bioscience, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 HBIOHarvard Bioscience, Inc.1 1 0 -
Is KMTS or HBIO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.753%.
-
Which is a Better Dividend Stock KMTS or HBIO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or HBIO?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 15.85x versus 0.29x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.15.85x -- $22.6M -$32.8M HBIOHarvard Bioscience, Inc.0.29x -- $20.6M -$1.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
